{
    "clinical_study": {
        "@rank": "127699", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin type A (BoNT-A) injection (Dysport\u00ae) Na\u00efve", 
                "description": "Subjects na\u00efve to BoNT-A treatment."
            }, 
            {
                "arm_group_label": "Botulinum toxin type A (BoNT-A) Pre-treated", 
                "description": "Subjects pre-treated with BoNT-A.\nInvestigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
            }
        ], 
        "brief_summary": {
            "textblock": "Botulinum toxin A (BoNT-A) is effective and safe in alleviating post-stroke spasticity and\n      reducing the burden of associated symptoms.\n\n      The hypothesis for this non-interventional study in arm spasticity (AS-NIS early BIRD) is no\n      significant difference between na\u00efve and pre-treated patients. The patients will be divided\n      in sub-groups according to the time interval between occurrence of stroke and start of\n      treatment (early, medium and late start of treatment according to the first and third\n      quartiles time distribution). It is hypothesized that the \"early\" start of treatment group\n      will have a reduced modified Ashworth scale (MAS) on the elbow and wrist flexors when\n      compared to the \"late\" start of treatment group."
        }, 
        "brief_title": "Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Post-stroke Arm Spasticity", 
        "condition_browse": {
            "mesh_term": [
                "Muscle Spasticity", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent prior to data collection\n\n          -  Hemiparesis and clinically relevant upper limb post-stroke spasticity (modified\n             Ashworth scale 1+ or more for elbow flexors and wrist flexors)\n\n          -  With the intention to be treated with Dysport\u00ae\n\n          -  BoNT na\u00efve or pre-treated with any BoNT product (If pre-treated, at least a 4 months\n             interval between last injection and inclusion)\n\n        Exclusion Criteria:\n\n          -  Fixed contractures at the upper limb\n\n          -  Recurrent stroke\n\n          -  Previous surgery to treat spasticity of the affected upper limb\n\n          -  Sensitivity to Dysport\u00ae or to its excipients or any other contraindications as given\n             in the local SmPC for Dysport\u00ae"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "25 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients suffering from post-stroke arm spasticity registered with Neurological clinics,\n        Rehab centers with BoNT out-patient clinics and neurological practices."
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840475", 
            "org_study_id": "A-94-52120-174"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hermagor", 
                        "country": "Austria"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "International, Multicenter, Non-interventional, Prospective, Longitudinal Study to Investigate the Effectiveness of Botulinum Toxin A (Dysport\u00ae) Injections in Patients Suffering From Post-stroke Arm Spasticity With Respect to Early, Medium or Late Start of Treatment.", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Andrea Reissig, PhD.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria: Agency for Health and Food Safety", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\"Early\" and \"late\" start of treatment according to the first and third quartiles time distribution between stroke and start of treatment with BoNT-A.\nInvestigation of effectiveness of BoNT-A treatment on the evolution of spasticity using MAS (sum of elbow and wrist flexors, EWF).", 
            "measure": "Comparison of modified Ashworth scale (MAS) between patients with early start of  treatment and patients with late start of treatment in the overall population (naive and pre-treated).", 
            "safety_issue": "No", 
            "time_frame": "Final study visit: approximately 20 months after first visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840475"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "\"Early\" and \"late\" start of treatment according to the first and third quartiles time distribution between stroke and start of treatment with BoNT-A.\nInvestigation of effectiveness of BoNT-A treatment on the evolution of spasticity using MAS (sum of elbow and wrist flexors, EWF).", 
            "measure": "Comparison of modified Ashworth scale (MAS) between patients with early start of treatment and patients with late start of treatment in the overall population (naive and pre-treated).", 
            "safety_issue": "No", 
            "time_frame": "Every 4 to 5 months starting from baseline up to 3 years"
        }, 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}